Case ReportQuetiapine and Gabapentin Dramatically Improve Treatment-resistant Schizoaffective Disorder in a Patient With a Long History of Cocaine AbuseWayne, Dennis MD; Madigan, Thomas RN, BSNAuthor Information From Mon Yough Community Services, McKeesport, PA. Supported by AstraZeneca Pharmaceuticals LP. Reprints: Dennis Wayne, MD, Medical Director, Mon Yough Community Services, 541 Fifth Avenue, McKeesport, PA 15132-2719 (e-mail: [email protected]). Addictive Disorders & Their Treatment: June 2004 - Volume 3 - Issue 2 - p 83-86 Buy Abstract Objective: To describe the successful use of quetiapine and gabapentin in a patient with treatment-resistant schizoaffective disorder and comorbid crack cocaine addiction. Case Report: This case report describes a 34-year-old man with a history of schizoaffective disorder, depression, and cocaine addiction. After numerous suicide attempts, repeated hospitalizations, and treatment with various conventional and atypical antipsychotics over a 10-year period, the patient showed dramatic improvement on a combination of quetiapine 800 mg/d and gabapentin 1200 mg/d. Over a 5-month period, his mood stabilized; he became less paranoid; he was able to cope better with his auditory hallucinations; and he had no cravings for crack cocaine. In addition, the concomitant administration of quetiapine and gabapentin in this patient caused no adverse events. Conclusion: The concomitant use of quetiapine and gabapentin may have beneficial effects in patients with schizo-affective disorder and comorbid cocaine addiction refractory to other medications. Controlled clinical trials are needed to confirm these findings. © 2004 Lippincott Williams & Wilkins, Inc.